Ready to start a weight loss journey? From GLP‑1 prescriptions to costs, we break down whether Hims customized weight loss plans make sense in 2026.

Whatever the reason driving you to a weight loss program, medical providers at Hims can get you started without leaving home today.

Hims & Hers stock dropped 77% from its high due to GLP-1 regulatory and legal pressure. Eucalyptus brings $450M in annualized revenue growing at triple-digit rates to Hims & Hers. Are you ahead, or ...

Hims & Hers Health HIMS-1.39%decrease; red down pointing triangle has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion as it seeks to expand its geographic reach.

Direct-to-consumer virtual care company Hims & Hers announced it has signed an agreement to acquire international digital health company Eucalyptus in a deal worth up to $1.15 billion. Eucalyptus is a ...

Shares of Hims & Hers Health rallied in early Thursday trading, after the health-and-wellness platform announced a deal to buy an Australia-based telehealth provider. The deal to buy Eucalyptus ...

Feb 19 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S.

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs. Federal regulators are seeking to rein in the online telemedicine platform ...

Hims & Hers Health is not out of the woods yet, sitting near yesterday's 17-month lows At last glance, shares of Hims & Hers Health Inc (NYSE:HIMS) are up 0.5% to trade at $15.91, after the wellness ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved by the agency. Last week, Hims & Hers announced ...